サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：臨床診断薬の世界市場：2023～2030年
市場調査レポート
商品コード
1350991

臨床診断薬の世界市場：2023～2030年

Global Clinical Diagnostics Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 133 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
臨床診断薬の世界市場：2023～2030年
出版日: 2023年08月15日
発行: Orion Market Research
ページ情報: 英文 133 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の臨床診断薬市場は、予測期間中（2023～2030年）にCAGR 6.3％で成長すると予測されています。市場拡大の背景には、革新的な診断検査の近代化が進んでいることがあります。次世代シーケンシング（NGS）、分子診断、新しい画像診断技術などの技術の進歩により、診断検査の精度と有効性が大幅に向上しています。前立腺がんを正確に認識し、その進行の程度を推定できる革新的なバイオマーカー検査を導入することは、患者管理にとって重要な意味を持つ可能性があります。この技術革新は、リスク層別化の改善、個別化された治療アプローチ、不必要な医療介入の削減につながる可能性があります。

ヘルスケア部門が精密医療と患者中心の治療を優先し続ける中、バイオマーカー検査の強化はこうした目的に合致しています。その結果、主要な市場参入企業は、高度なバイオマーカー検査に対する需要の高まりに対応するため、新規製品を積極的に投入しています。例えば、クエスト・ダイアグノスティックスは2023年7月、エンビジョン・サイエンシズのサブスペシャリティ病理子会社アメリパスと共同で革新的な前立腺がんバイオマーカー検査を発売しました。オーストラリアの臨床診断薬企業であるエンビジョン・サイエンシズ社（Envision Sciences Pty Ltd.）は、バイオマーカーの可能性を活用し、がんの診断と予後のための血液と組織ベースの検査ポートフォリオの開発に取り組んでいます。

このようなイノベーションへの集中的な取り組みは、診断能力の向上への業界の献身を浮き彫りにし、最先端の技術や手法を通じて患者ケアを前進させるというコミットメントを強調しています。

セグメント別の展望

脂質パネルが世界の臨床診断薬市場で大きなシェアを占めると予測される

検査項目の中でも、脂質パネルのサブセグメントが世界の臨床診断薬市場で大きなシェアを占めると予想されています。同分野の成長の背景には、健康意識の高まりがあります。最適/善玉コレステロール値を維持することの重要性に対する理解が深まったため、脂質パネル検査を選択し、心血管系の健康についてヘルスケア専門家と話し合う個人が増加しています。例えば、2023年6月に英国心臓財団（British Heart Foundation）は、心臓・循環器疾患には心臓や血管に関連する様々な疾患が含まれると報告しています。これらの疾患には、遺伝性疾患、冠動脈性心疾患、心房細動、心不全、脳卒中、血管性認知症などが含まれます。心臓病や循環器系疾患に罹患している人の数は世界で約6億2,000万人であり、この数はライフスタイルの変化、高齢化、心臓発作や脳卒中後の生存率の向上により増加の一途をたどっています。世界では約13人に1人がこれらの疾患を抱えて生活していると推定されています。2019年には、2億9,000万人の女性と2億6,000万人の男性が心臓病や循環器疾患を患っています。1997年以来、この数は2億8,500万人から6億2,000万人へとエスカレートし、2倍以上になっています。最も一般的な疾患は、冠動脈性心疾患、末梢血管疾患、脳卒中、心房細動です。毎年、世界中で推定6,000万人が心臓病や循環器疾患を発症しています。

2019年の冠動脈性心疾患の罹患率は870万人、末梢血管疾患は450万人、脳卒中は840万人、心房細動は130万人でした。心臓・循環器疾患とその健康への影響に対する意識の高まりは、診断検査と医療指導に対する需要の増加につながり、特定の市場セグメントの成長を促しています。

地域別展望

世界の臨床診断薬市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、世界のその他の地域（中東とアフリカ、中南米）を含む地域別にさらに細分化されています。このうち、北米が世界市場で突出したシェアを占めると予想されています。この成長は、検査室検査の重要性を理解する患者の増加、感染症や長期的な疾病を患う患者の増加によるものです。例えば、2022年に発表された米国がん協会の報告書によると、米国では約190万人が新たにがんと診断されました。

アジア太平洋地域は世界の臨床診断薬市場において著しいCAGRで成長する見込み

全地域の中で、アジア太平洋地域は予測期間中にかなりのCAGRで成長すると予測されています。この地域の成長は、疾病の早期発見に対する需要の高まりに起因しています。病気を初期段階で特定できる診断検査は、治療成功の可能性を高め、関連するヘルスケアコストを削減できる可能性があるため、有益であると考えられています。地域全体における診断センターのさらなる拡大が、市場成長にとって有利な条件を生み出しています。例えば、2023年2月、Centre for Cellular and Molecular Platforms（C-CAMP）はニューデリーでNational Diagnostics Catapult（C-CAMP InDx 2.0）を立ち上げました。このカタパルト（C-CAMP InDx 2.0）は、既存および潜在的なパンデミックに対するインドの準備態勢を強化し、COVID-19のような伝染病の診断領域を拡大することを目的としています。さらに、C-CAMP InDx 2.0は、中低所得国（LMICs）における診断薬分野の能力構築のための世界モデルを構築し、ユニバーサル・ヘルス・カバレッジの世界的ビジョンにあるアフォーダビリティとアクセシビリティという2つの目標を達成することを目的としています。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Bio-Rad Laboratories, Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Danaher Corp.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Sysmex Corp.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 臨床診断薬の世界市場：検査別
    • 脂質パネル
    • 肝臓パネル
    • 腎臓パネル
    • 完全血算
    • 電解質検査
    • 感染症検査
    • その他（遺伝子検査、心電図検査、心臓負荷検査）
  • 臨床診断薬の世界市場：製品別
    • 検査機器
    • 試薬
    • その他（アッセイ、キット）
  • 臨床診断薬の世界市場：エンドユーザー別
    • 病院検査室
    • 診断ラボ
    • ポイントオブケア検査

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Abbott
  • Cepheid
  • Charles River Laboratories International, Inc.
  • Exact Sciences Corp.
  • Flagship Biosciences, Inc.
  • FUJIFILM Holdings Corp.
  • LGC Clinical Diagnostics
  • Merck Group
  • NeoGenomics Laboratories, Inc.
  • Ortho Clinical Diagnostics
  • SCIEX
  • Sonic Healthcare Ltd.
  • Thermo Fisher Scientific
図表

LIST OF TABLES

  • 1. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 2. GLOBAL LIPID CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL LIVER CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL RENAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL COMPLETE BLOOD COUNT CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ELECTROLYTE TESTING CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL INFECTIOUS DISEASE TESTING CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL OTHERS CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 9. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 10. GLOBAL INSTRUMENTS BASED CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 11. GLOBAL REAGENTS BASED CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 12. GLOBAL OTHER PRODUCTS BASED CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 13. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. GLOBAL CLINICAL DIAGNOSTICS IN HOSPITAL LABORATORY MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 15. GLOBAL CLINICAL DIAGNOSTICS IN DIAGNOSTIC LABORATORY MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 16. GLOBAL CLINICAL DIAGNOSTICS IN POINT-OF-CARE TESTING MARKET RESEARCH AND ANALYSIS, 2022-2030 ($ MILLION)
  • 17. GLOBAL CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 22. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 24. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 26. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 27. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 29. ASIA- PACIFIC CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 30. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TEST, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY PRODUCT, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE BY TEST, 2022 VS 2030 (%)
  • 2. GLOBAL LIPID CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL LIVER CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL RENAL CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL COMPLETE BLOOD COUNT CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ELECTROLYTE TESTING CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL INFECTIOUS DISEASE TESTING CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL OTHERS CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 9. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE BY PRODUCT, 2022 VS 2030 (%)
  • 10. GLOBAL INSTRUMENTS BASED CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL REAGENTS BASED CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL OTHER PRODUCTS BASED CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. GLOBAL CLINICAL DIAGNOSTICS IN HOSPITAL LABORATORY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CLINICAL DIAGNOSTICS IN DIAGNOSTIC LABORATORY MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL CLINICAL DIAGNOSTICS IN POINT-OF-CARE TESTING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CLINICAL DIAGNOSTICS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CLINICAL DIAGNOSTICS MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027585

Title: Global Clinical Diagnostics Market Size, Share & Trends Analysis Report by Test (Lipid Panel, Liver Panel, Renal Panel, Complete Blood Count, Electrolyte Testing, Infectious Disease Testing, and Others), by Product (Instruments, Reagents, and Others), and by End-User (Hospital Laboratory, Diagnostic Laboratory, and Point-of-Care Testing),Forecast Period (2023-2030).

The global clinical diagnostics market is anticipated to grow at a CAGR of 6.3% during the forecast period (2023-2030). The market expansion is attributed to the ongoing modernization of innovative diagnostic tests. Technological advancements, such as next-generation sequencing (NGS), molecular diagnostics, and new imaging techniques, have substantially enhanced the precision and efficacy of diagnostic tests. Introducing an innovative biomarker test capable of accurately recognizing prostate cancer and estimating the severity of its progression could have significant implications for patient management. This innovation has the potential to lead to improved risk stratification, personalized treatment approaches, and a reduction in unnecessary medical interventions.

The development of enhanced biomarker testing is consistent with these objectives as the healthcare sector continues to prioritize precision medicine and patient-centered treatment. Consequently, key market players are actively introducing novel products to meet the rising demand for advanced biomarker tests. For instance, in July 2023, Quest Diagnostics launched an innovative prostate cancer biomarker test in collaboration with Envision Sciences' sub-specialty pathology subsidiary AmeriPath. Envision Sciences Pty Ltd., an Australian clinical diagnostics enterprise, is engaged in developing a portfolio of blood and tissue-based tests for cancer diagnosis and prognosis, leveraging the potential of biomarkers.

This concentrated focus on innovation highlights the industry's dedication to enhance diagnostic capabilities and emphasizes its commitment to advancing patient care through state-of-the-art technologies and methodologies.

Segmental Outlook

The global clinical diagnostics market is segmented by test, product, and end-user. Based on the test, the market is sub-segmented into lipid panels, liver panels, renal panels, complete blood counts, electrolyte testing, infectious disease testing, and others. Based on the product, the market is sub-segmented into instruments, reagents, and others. Further, on the basis of end-user, the market is sub-segmented into hospital laboratories, diagnostic laboratories, point-of-care testing, and others. Among the end-users, the point-of-care testing sub-segment is anticipated to hold a considerable share of the market owing to the healthcare industry's significant shift towards decentralization along with the rapidly increasing utilization of point-of-care diagnostic products.

The Lipid Panel Sub-Segment is Anticipated to Hold a Considerable Share of the Global Clinical Diagnostics Market

Among the tests, the lipid panel sub-segment is expected to hold a considerable share of the global clinical diagnostics market. The segmental growth is attributed to the growing health awareness. More individuals are opting for lipid panel tests and engaging in discussions with healthcare professionals about their cardiovascular well-being owing to increased understanding of the importance of maintaining optimal/ good cholesterol levels. For instance, in June 2023, the British Heart Foundation reported that heart and circulatory diseases encompass a variety of conditions related to the heart and blood vessels. These conditions include inherited diseases, coronary heart disease, atrial fibrillation, heart failure, stroke, and vascular dementia. The global count of individuals affected by heart or circulatory diseases is approximately 620 million, and this number continuous to increase due to changing lifestyles, an aging population, and improved survival rates following heart attacks and strokes. Approximately 1 in 13 people globally are estimated to live with these conditions. In 2019, there were 290 million women and 260 million men living with heart or circulatory diseases. Since 1997, this count has more than doubled, escalating from 285 million to 620 million. The most common conditions are coronary heart disease, peripheral vascular disease, stroke, and atrial fibrillation. Every year, an estimated 60 million individuals globally develop heart or circulatory diseases.

In 2019, the incidence rate for coronary heart disease was 8.7 million, for peripheral vascular disease was 4.5 million, for stroke was 8.4 million, and for atrial fibrillation was 1.3 million. This growing awareness of heart and circulatory diseases and their impact on health has led to an increased demand for diagnostic tests and medical guidance, subsequently driving the growth of specific market segments.

Regional Outlook

The global clinical diagnostics market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe. This growth is contributed owing to the higher patient understanding the importance of laboratory tests, and a rise in the number of individuals with infectious and long-term illnesses. For instance, around 1.9 million new cancer cases were diagnosed in the US, according to the American Cancer Society report published in 2022.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Clinical Diagnostics Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing demand for early detection of diseases. Diagnostic tests that can identify diseases in their initial stages are considered beneficial, as they may improve the chances of successful treatment and potentially reduce associated healthcare costs. Further expansion of diagnostic centers across the region is creating favorable conditions for the growth of the market. For instance, in February 2023, The Centre for Cellular and Molecular Platforms (C-CAMP) launched the National Diagnostics Catapult (C-CAMP InDx 2.0) in New Delhi. The Catapult, C-CAMP InDx 2.0, is intended to strengthen India's readiness for existing and potential pandemics and expand the diagnostic area for contagious diseases, such as COVID-19. Furthermore, the Catapult is designed to create a global model for capacity building in the diagnostics field in lower- and middle-income countries (LMICs) to accomplish the two objectives of affordability and accessibility in the global vision for Universal Health Coverage.

Market Players Outlook

The major companies serving the clinical diagnostics market include: Abbott, Cepheid, Charles River Laboratories International, Inc., Exact Sciences Corp., Flagship Biosciences, Inc., and others. The market players are considerably contributing to market growth through the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in May 2022, Qiagen Inc. launched the NeuMoDxHSV 1/2 Quant Assay for the quantification and differentiation of herpes simplex virus type 1 (HSV-1) DNA and/or herpes simplex virus type 2 (HSV-2) with approval from the European Commission.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global clinical diagnostics market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bio-Rad Laboratories, Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Danaher Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Sysmex Corp.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Clinical Diagnostics Market by Test
    • 4.1.1. Lipid Panel
    • 4.1.2. Liver Panel
    • 4.1.3. Renal Panel
    • 4.1.4. Complete Blood Count
    • 4.1.5. Electrolyte Testing
    • 4.1.6. Infectious Disease Testing
    • 4.1.7. Others (Genetic Testing, Electrocardiography, and Cardiac Stress Test)
  • 4.2. Global Clinical Diagnostics Market by Product
    • 4.2.1. Instruments
    • 4.2.2. Reagents
    • 4.2.3. Others (Assays, and Kits)
  • 4.3. Global Clinical Diagnostics Market by End-User
    • 4.3.1. Hospital Laboratory
    • 4.3.2. Diagnostic Laboratory
    • 4.3.3. Point-of-Care Testing

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Abbott
  • 6.2. Cepheid
  • 6.3. Charles River Laboratories International, Inc.
  • 6.4. Exact Sciences Corp.
  • 6.5. Flagship Biosciences, Inc.
  • 6.6. FUJIFILM Holdings Corp.
  • 6.7. LGC Clinical Diagnostics
  • 6.8. Merck Group
  • 6.9. NeoGenomics Laboratories, Inc.
  • 6.10. Ortho Clinical Diagnostics
  • 6.11. SCIEX
  • 6.12. Sonic Healthcare Ltd.
  • 6.13. Thermo Fisher Scientific